Vascular Hemostatic Disorders

Download PDF

Recent Publications on Vascular Hemostatic Disorders:
The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA. Phase III clinical trials help define standard therapies by comparing the...	11th July, 2008	Edwards Comprehensive Cancer Center, Marshall University, Huntington, West	Cancer Invest. 2008 Jun;26(5):445-7. DOI Direct Link
Modern treatment options for elderly patients with multiple myeloma. Multiple myeloma, an incurable malignancy of plasma cells, is a disease of...	11th July, 2008	Klinik fur Hamatologie und Onkologie, Stadtische Kliniken Bielefeld gGmbH,	Onkologie. 2008 Jun;31(6):335-42. Epub 2008 May 27. DOI Direct Link
Extensive Osler-Rendu disease in a breast cancer patient: increasing hepatic arteriovenous malformations under endocrine therapy mimicking liver metastases. BACKGROUND: Undefined, increasing hepatic lesions are a common issue in...	11th July, 2008	University of Heidelberg, Medical School, Department of Gynecology and	Onkologie. 2008 Jun;31(6):328-31. Epub 2008 May 27. DOI Direct Link
Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice. Phase III clinical trials help define standard therapies by comparing the...	9th July, 2008	Hemaology Department, University of Salamanca, Salmanca, Spain	Clin Adv Hematol Oncol. 2008 Apr;6(4):s4-s10.
Neurological picture. Breach rhythm related to a solitary skull lesion caused by multiple myeloma. Today several monoclonal antibodies, including the anti-CD20 antibody...	9th July, 2008	Department of Clinical Neurophysiology, Erasmus MC, University Medical	J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):819. DOI Direct Link
→View more research publications.

Vascular Hemostatic Disorders Clinical Trials:
Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy	Multiple Myeloma
A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning	Multiple Myeloma
Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma	Multiple Myeloma
A Novel Vaccine for the Treatment of MUC1-Expressing Tumor Malignancies	Multiple Myeloma;   Tumors
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma	Multiple Myeloma
→View more trials.

BioPortfolio Ltd. offers e-mail and postal lists for Vascular Hemostatic Disorders scientists - we have details of around 4304 individuals working on Vascular Hemostatic Disorders .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.